Atezolizumab/bevacizumab for non-squamous NSCLC with high PD-L1 expression

First-line atezolizumab plus bevacizumab showed promising results in patients with non-squamous, PD-L1-positive non-small cell lung cancer (NSCLC).

Preclinical models have shown that bevacizumab enhances the antitumor activity of PD-1/PD-L1 antibodies [1]. Therefore, the single-arm phase 2 WJOG@Be Study evaluated the clinical benefits of adding bevacizumab (15 mg/kg every 3 weeks ) to atezolizumab (1,200 mg every 3 weeks) in the first-line [2]. Patients were eligible if they had pathologically confirmed advanced non-squamous NSCLC without any EGFR/ALK/ROS1 alterations, and PD-L1 tumour proportion score ≥50%. A total of 39 patients were enrolled and treated until progression.

Objective response rate was 64.1% (25/39), all partial responses. Median progression-free survival (PFS) was 15.9 months and PFS rate at 1 year was 54.9%. Overall survival rate at 1 year was 70.6%. The treatment was discontinued in 19 patients, 17 due to disease progression and 2 due to immune-related adverse events. No grade 4/5 toxicity was observed.

1. Hegde P, et al. Semin Cancer Biol 2017;52:117-124.
2. Seto T, et al. WJOG @Be study: A phase II study of atezolizumab (atez) with bevacizumab (bev) for non-squamous (sq) non-small cell lung cancer (NSCLC) with high PD-L1 expression. ESMO 2020 Virtual Meeting, abstract LBA55.

Posted on 25 November 202024 November 2020